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Innovations
Fluidigm
Biochips Get Indoor Plumbing
a process dubbed “multi-layer soft nels. The components of the chip
are spatially addressable, enablinglithography.” The material they use
the results to be read by standardis a soft silicone elastomer—a pli-
Today’s biotechnology abounds
with buzzwords—from genomics
and proteomics to biochips and mi-
croarrays—and for good reason. chip-readers. Moreover, the elasto-able, gas permeable, rubbery mate-
These terms were coined to de- mer material itself is gas permeable,rial that can be spun out on a mold
scribe the new concepts and tools allowing cells to thrive for weeksand cured. The mold is a flat surface
that are revolutionizing the way bio- within its confines.with raised channels created by
logical research is being done. In- The technology originated withphotolithography. Two such layers
dustrial biology is becoming both the work of Fluidigm founder Ste-fused face-to-face onto a glass slide
smaller and larger at the same time, phen R. Quake. Quake studied phys-can create a three-dimensional,
and the analogies with the revolution ics at Stanford, along with goodchannel-containing chip. The bot-
in computing power and computing friend and Fluidigm CEO and co-tom, sample layer contains channels
tools in the last century continue to founder Gajus Worthington. Quakethrough which flow both reagents
resonate. Miniaturization is bringing was an academic scientist at heart,
the economies of scale into the de- whereas Worthington had an inter-
sign of biochips, a market that is al- est in entrepreneurship. While
“We have attacked thisready approaching a billion dollars Quake ascended quickly to a faculty
position at Caltech in Southern Cali-annually. The race is on to develop problem by developing a
integrated devices that can perform fornia, Worthington sought out men-microprocessor that crys-
complex biological assays in a mas- tors to teach him the art of building
tallizes proteins in situ withsively parallel format. Not only are a business. With the aim of “learning
by example,” he joined a high techthese tools boosting throughput, two orders of magnitude
they are vastly reducing the cost of company called Actel. By 1998,less sample than currentvery expensive and often very lim- Worthington’s self-apprenticeship
techniques and with inte-ited biological samples. felt complete, and he decided that
it was time for him to make a move.In the last few years, a new tech- grated fluid handling,”
nology, and hence a new term, have “A key attribute essential for entre-says Worthington, ex-made their appearance: microflui- preneurship is the sense of when the
plaining that “the devicedics. As biochips become closer in time is ripe, and the decisiveness to
act without hesitation,” says Wor-size to the cells and molecules on makes use of a process
which they work, so too must the thington, “and in 1998, I knew thatcalled free interface diffu-channels, pumps, and valves that it was time for me to make a move.”
sion, and several bio-manipulate the solutions of reagents As it happens, Worthington did not
know what it was that he would beand substrates. A chip intended to logically important pro-
handle thousands of microquanti- doing, but serendipitously, it wasteins resistant to standardties of biological samples must be just then that he heard from his old
pal Quake. “Steve emailed me a pre-able to store, aliquot, and mix these techniques have been
reagents and then provide some print of a paper on his microfluidicscrystallized with the tech-
means of measuring the activity of work, and it was clear to me that the
nology.”interest. However, as the engineers commercial potential of the technol-
of macro systems of a century ago ogy was mammoth.”
found, one quickly runs into the When asked whether he had any
and substrates, under the influenceproblem referred to as the “tyranny trepidation about going into busi-
of pressure changes in the channelsof numbers” —the practical limit to ness with an old friend, Worthington
of the upper control layer. A detailedthe complexity of assembled sys- provides an emphatic no. “I had very
demonstration of Fluidigm’s soft li-tems. A South San Francisco com- clear expectations going in that this
thography process can be found onpany called Fluidigm appears to would require a lot of sacrifice and
their website (www.fluidigm.com).have solved this problem—on the pain, and the only way to succeed
Sophisticated design of variousmicro scale at least—by building was to work with someone with
control and fluid layers can produceupon a powerful new technology to whom I had only the greatest per-
chips that can simultaneously per-design and create complex, fully in- sonal and professional regard.”
form multiple, complex reactions ontegrated, microfluidic devices. Both Worthington and Quake
literally thousands of samples—allTheir solution is to fabricate the wanted to develop an idea with lon-
controlled by manipulating the airpumps and valves directly into the gevity and wanted to make real, tan-
gible products. Such an idea wasmicrofluidic circuitry of the chip—by pressure within the control chan-
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almost anathema at the time—the ence Online, doi:10.1126/science. lion in Series C financing from a
group of venture capital investorsinternet was white hot, and back- 1076996). The device is able to ad-
dress and recover the contents ofof-the-envelop ideas abounded. “In led by Lehman brothers, providing
needed capital to begin bringing its1999, most VCs interested in bio- one among thousands of picoliter
chambers within the chip for furthermedical applications were thinking products to market. It has also
signed an agreement to providee-health—they had almost aban- investigation, “opening up the pos-
sibility of many new applications,doned traditional biotechnology.” In GlaxoSmithKline with microfluidic
systems. Of course, Fluidigm is notthis atmosphere, venture funding both scientific and commercial,” ac-
cording to Quake.was out, so the pair went after the only act in town, as Aclara Bio-
sciences and Caliper technologies“angels,” private individuals looking But the “killer ap” of choice is the
Topaz product for protein crystalli-for investment opportunities. Angels have developed more traditional mi-
crofluidic devices based on moldedtend to provide support to busi- zation, currently available as a pro-
totype product and expected to benesses that are in a very early stage plastic and glass, respectively. Both
groups use electric current or pres-of development, relying on their gut widely launched sometime next
year. Drug developers have a keeninstincts about the power of an idea sure differentials to move fluid
through their devices, which areor a technology, rather than the ex- interest in determining the three-
dimensional structure of proteinsacting demands of the process of already on the market and make use
of commercially available robotsdue diligence that often come with involved in human pathogenesis. Al-
though great advances in technol-venture capital. and readers. Surface Logix (www.
surfacelogix.com) in Boston alsoBacked by Quake’s technology ogy have been made recently, the
process remains costly and cumber-and Caltech’s endorsement, they uses soft lithography to create a
complementary set of chips for bio-managed to interest a leading entre- some—and still very much an eso-
teric art. “We have attacked thispreneur in the southern California logical assays, but they have not in-
tegrated microfluidics into their de-area, Bruce Burrows, who brought problem by developing a micropro-
cessor that crystallizes proteins in$3 million to the table. The cash al- sign at this point.
The proof is in the pudding, aslowed them to flesh out areas for situ with two orders of magnitude
less sample than current techniquesproduct application and to create they say, and Fluidigm’s future de-
pends largely on the outcome of thethe tools to integrate the valves and and with integrated fluid handling,”
says Worthington, explaining thatpumps on the chip. They were also tests now underway of its inaugural
Topaz product. Worthington andable to recruit renowned biotechnol- “the device makes use of a process
called free interface diffusion, andogy IP attorney Bill Smith as their Quake are optimistic, as the results
so far are better than expected. Theygeneral counsel. By 2000, biotech- several biologically important pro-
teins resistant to standard tech-nology was back in vogue with the are also confident that this is only
the beginning for the technology andVC community, allowing the duo to niques have been crystallized with
the technology.” Free interface dif-raise $11.5 million on the strength of the company. “Our pace of integra-
tion has been dramatically fasterthe technology, their strong IP posi- fusion is widely regarded as superior
to conventional crystallization tech-tion, and the applications they envis- than even Moore’s law,” says Wor-
thington. “Since invention of the firstaged in industrial biology. The group niques because the process is effec-
tively equivalent to testing a multi-continued to develop the technol- valve, Fluidigm and the Quake lab at
Caltech have increased integrationogy, demonstrating a 100-fold in- tude of conventional crystallization
conditions simultaneously. “It is likecrease in the number of valves inte- by a factor of 10 each year.” Only 2
years have passed, however, but thegrated into chips. They established mapping out the contour of a moun-
tain with roads instead of one dis-a pilot production facility, filled out results do compare favorably to
Moore’s law, which holds that mi-their executive team, and secured crete point at a time,” Worthington
explains. “We are able to miniaturizetheir first partnership with big pha- croprocessor complexity doubles
every 18 months. Today, the grouprma giant GlaxoSmithKline. the process because of our on-chip
valve technology.” A key advantageFluidigm’s commanding IP posi- is able to fabricate devices with up
to 25,000 working valves, and theytion afforded the company a tech- of the device is the ability to test a
foresee reaching 100,000 before notnology platform that was difficult for wide array of crystallization condi-
too long. “That level of integrationcompetitors to replicate. What they tions with miniscule amounts of pre-
will allow us to market devices thatnow needed, according to Worthin- cious protein sample. Production of
eliminate the robots in use in manygton, was the “killer application.” these protein samples is a critical
labs today,” says Worthington. “WeVarious devices have been develop- bottleneck in the crystallization pro-
plan to end the ‘tyranny of pi-ed, at least in prototype, including cess. The product has already
petting,’” jokes Quake.a “genetic microprocessor” able to shipped out to several undisclosed
test sites in big pharma, the biotechperform 20,000 PCR reactions in
Chemistry & Biology invites yourparallel for use in genotyping, a mi- industry, and in academia.
comments on this topic. Pleasecrofluidic cell sorter, and a miniature In this age of dwindling bank ac-
write to the editors at chembiol@immunoassay array. More recently, counts for many biotech companies,
cell.com.Quake’s laboratory has developed a with scant hope of a top-up for
many, it is important to note that atmicrofluidic memory storage device Robert M. Frederickson is a biotech writer
whose behavior is reminiscent of the end of 2001, Fluidigm did suc- based in the San Diego area (rfreder@
yahoo.com).random access memory (see Sci- ceed in raising an additional $37 mil-
